Abingdon Health Plc (ABDX.L) Research

Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-acting diagnostic for COVID-19 IgG antibodies, alongside various nucleic acid lateral flow immunoassays. They also offer Seralite, a swift lateral flow test for accurately measuring kappa and lambda immunoglobulin free light chains in blood serum. Additionally, their AppDx technology converts any smartphone into an autonomous and adaptable lateral-flow reader. Beyond these offerings, the company provides expert services in lateral flow development and manufacturing, as well as advisory support to firms in the health tech industry. Abingdon Health Plc also engages in a collaborative and co-marketing partnership with Abcam plc.

Market snapshot

Symbol
ABDX.L
Price
$11.25
Day change
-2.17%
Market cap
$21.8M
P/E ratio
-13.39x
52-week range
5.1-13
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 5 months

Peer companies

  • ANGLE plc (AGL.L)
  • Cambridge Cognition Holdings Plc (COG.L)
  • Fusion Antibodies plc (FAB.L)
  • Genedrive Plc (GDR.L)
  • Genflow Biosciences plc (GENF.L)
  • GENinCode plc (GENI.L)
  • IXICO plc (IXI.L)
  • Proteome Sciences plc (PRM.L)

Open Abingdon Health Plc (ABDX.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.